Sanofi is a leading global biopharmaceutical company founded in 1973, headquartered in Paris, France. It is research and development-driven, leveraging artificial intelligence to power innovations in healthcare.

The company is dedicated to improving lives through the discovery, development, and distribution of innovative medicines and vaccines. Sanofi’s portfolio spans specialty care and general medicines, targeting a wide range of therapeutic areas including cardiovascular diseases, diabetes, immunology, inflammation, infectious diseases, oncology, neurology, rare blood disorders, and vaccines.

Sanofi markets over 90 drugs in the United States and globally offers products addressing both communicable and non-communicable diseases. It is recognized for its governance in access to medicine and has a strong performance in research and development as well as product delivery.

In recent years, the company has expanded its capabilities through notable acquisitions, such as Provention Bio Inc. in 2023 and Inhibrx Inc. in 2024, contributing to its extensive product range and innovation pipeline.

Sanofi’s vaccine portfolio targets significant infectious diseases including lower respiratory infections, tetanus, and meningitis, while its medicines address major global health challenges like cardiovascular conditions, diabetes, cancer, malaria, and tuberculosis. The company also addresses neglected tropical diseases and maternal and neonatal conditions.

Overall, Sanofi stands out as a leading biopharma entity combining advanced research with technology to deliver impactful healthcare solutions worldwide.